US 11,807,690 B2
Hyperglycosylated binding polypeptides
Clark Pan, Sutton, MA (US); Huawei Qiu, Westborough, MA (US); Pradeep Dhal, Westford, MA (US); Bo Chen, Boston, MA (US); and Diego Gianolio, Somerville, MA (US)
Assigned to GENZYME CORPORATION, Cambridge, MA (US)
Filed by Genzyme Corporation, Cambridge, MA (US)
Filed on Oct. 17, 2019, as Appl. No. 16/655,500.
Application 16/655,500 is a division of application No. 15/614,015, filed on Jun. 5, 2017, granted, now 10,494,439.
Application 15/614,015 is a division of application No. 14/203,438, filed on Mar. 10, 2014, granted, now 9,701,753, issued on Jul. 11, 2017.
Claims priority of provisional application 61/776,724, filed on Mar. 11, 2013.
Claims priority of provisional application 61/776,715, filed on Mar. 11, 2013.
Claims priority of provisional application 61/776,710, filed on Mar. 11, 2013.
Prior Publication US 2020/0140564 A1, May 7, 2020
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61K 47/54 (2017.01); C07K 16/32 (2006.01); C07K 16/40 (2006.01)
CPC C07K 16/2893 (2013.01) [A61K 47/549 (2017.08); A61K 47/6803 (2017.08); A61K 47/6869 (2017.08); A61K 47/6889 (2017.08); C07K 16/28 (2013.01); C07K 16/2809 (2013.01); C07K 16/2851 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); C07K 2317/40 (2013.01); C07K 2317/41 (2013.01); C07K 2317/522 (2013.01); C07K 2317/56 (2013.01); C07K 2317/71 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01)] 17 Claims
 
1. A method of treating HER2 positive cancer in a patient in need thereof comprising administering an effective amount of a composition comprising: an antibody, or antigen binding fragment thereof, that binds to human HER2 and comprises a CH1 domain,
wherein the CH1 domain comprises an asparagine residue at amino acid position 114, according to Kabat numbering.